Current Report Filing (8-k)
February 06 2017 - 4:06PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
February
6, 2017
ARIAD
Pharmaceuticals, Inc.
(Exact
name of registrant as specified in its charter)
Delaware
|
001-36172
|
22-3106987
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(I.R.S.
Employer
Identification
No.)
|
125 Binney Street, Cambridge, Massachusetts
|
02142
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's telephone number, including
area code:
(617) 494-0400
Not
Applicable
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any
of the following provisions
(
see
General Instruction A.2.
below)
:
⃞
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
⃞
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
⃞
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
⃞
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
In the press release dated February 6, 2017, ARIAD Pharmaceuticals, Inc.
(“ARIAD” or the “Company”) announced the submission of a Marketing
Authorization Application (MAA) for its investigational oral anaplastic
lymphoma kinase (ALK) inhibitor, brigatinib, to the European Medicines
Agency (EMA). ARIAD is seeking marketing approval in the European Union
of brigatinib in adult patients with anaplastic lymphoma kinase (ALK+)
non-small cell lung cancer (NSCLC) who have been previously treated with
crizotinib. The U.S. Food and Drug Administration (FDA) is currently
reviewing a New Drug Application for brigatinib filed by ARIAD and has
set an action date of April 29, 2017 under the Prescription Drug User
Fee Act (PDUFA).
A copy of the press release is being filed herewith as Exhibit 99.1 and
is incorporated by reference herein.
ITEM 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
|
Exhibit
|
|
Description
|
|
99.1
|
|
Press release dated February 6, 2017
|
The press release may contain hypertext links to information on our
websites. The information on our websites is not incorporated by
reference into this Current Report on Form 8-K and does not constitute a
part of this Form 8-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
|
ARIAD Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Manmeet S. Soni
|
|
|
|
|
|
Manmeet S. Soni
|
|
|
|
|
|
Executive Vice President, Chief Financial Officer
|
|
|
|
|
|
Date:
|
February 6, 2017
|
|
|
|
Exhibit List.
|
Exhibit
|
Description
|
|
|
|
|
99.1
|
Press release dated February 6, 2017
|
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ariad (NASDAQ:ARIA)
Historical Stock Chart
From Jul 2023 to Jul 2024